184 related articles for article (PubMed ID: 10617242)
1. Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up.
Aschan J; Carlens S; Hägglund H; Klaesson S; Mattsson J; Remberger M
Clin Transplant; 1999 Dec; 13(6):512-9. PubMed ID: 10617242
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic bone marrow transplantation for chronic myeloid leukemia: a retrospective study of busulfan-cytoxan versus total body irradiation-cytoxan as preparative regimen in Koreans.
Kim I; Park S; Kim BK; Chang HM; Bang SM; Byun JH; Kim DJ; Min WS; Kim HJ; Kim CC
Clin Transplant; 2001 Jun; 15(3):167-72. PubMed ID: 11389706
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM).
Devergie A; Blaise D; Attal M; Tigaud JD; Jouet JP; Vernant JP; Bordigoni P; Ifrah N; Dauriac C; Cahn JY
Blood; 1995 Apr; 85(8):2263-8. PubMed ID: 7718899
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
5. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Ringdén O; Labopin M; Tura S; Arcese W; Iriondo A; Zittoun R; Sierra J; Gorin NC
Br J Haematol; 1996 Jun; 93(3):637-45. PubMed ID: 8652385
[TBL] [Abstract][Full Text] [Related]
6. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients.
Aschan J; Ringdén O; Andström E; Ljungman P; Lönnqvist B; Remberger M
Bone Marrow Transplant; 1994 Jul; 14(1):79-87. PubMed ID: 7951124
[TBL] [Abstract][Full Text] [Related]
7. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.
Blume KG; Kopecky KJ; Henslee-Downey JP; Forman SJ; Stiff PJ; LeMaistre CF; Appelbaum FR
Blood; 1993 Apr; 81(8):2187-93. PubMed ID: 8471778
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia.
Dusenbery KE; Daniels KA; McClure JS; McGlave PB; Ramsay NK; Blazar BR; Neglia JP; Kersey JH; Woods WG
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):119-28. PubMed ID: 7995742
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.
Anderson JE; Appelbaum FR; Schoch G; Gooley T; Anasetti C; Bensinger WI; Bryant E; Buckner CD; Chauncey T; Clift RA
J Clin Oncol; 1996 Jan; 14(1):220-6. PubMed ID: 8558201
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Sun ZM; Liu HL; Wu Y; Geng LQ; Zheng CC; Tang BL; Zhu XY; Tong J; Wang XB; Ding KY; Wan X; Zhang L; Yao W; Zhang XH; Han YS; Yang HZ; Liu X; Zhu WW; Wu JS; Wang ZY
Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(28):2214-9. PubMed ID: 27480651
[TBL] [Abstract][Full Text] [Related]
12. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.
Socié G; Clift RA; Blaise D; Devergie A; Ringden O; Martin PJ; Remberger M; Deeg HJ; Ruutu T; Michallet M; Sullivan KM; Chevret S
Blood; 2001 Dec; 98(13):3569-74. PubMed ID: 11739158
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
14. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
[TBL] [Abstract][Full Text] [Related]
15. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.
Clift RA; Buckner CD; Thomas ED; Bensinger WI; Bowden R; Bryant E; Deeg HJ; Doney KC; Fisher LD; Hansen JA
Blood; 1994 Sep; 84(6):2036-43. PubMed ID: 8081005
[TBL] [Abstract][Full Text] [Related]
16. Autologous bone marrow transplantation in acute myeloid leukemia: the University of Minnesota experience.
Dusenbery KE; Steinbuch M; McGlave PB; Ramsay NK; Blazar BR; Neglia JP; Litz C; Kersey JH; Woods WG
Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):335-43. PubMed ID: 8892457
[TBL] [Abstract][Full Text] [Related]
17. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
[TBL] [Abstract][Full Text] [Related]
18. Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study.
Wang YH; Tien FM; Tsai CH; Huang HH; Liu JH; Liao XW; Tang JL; Yao M; Ko BS
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1488. PubMed ID: 34196132
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary complications of bone marrow transplantation: a comparison of total body irradiation and cyclophosphamide to busulfan and cyclophosphamide.
Hartsell WF; Czyzewski EA; Ghalie R; Kaizer H
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):69-73. PubMed ID: 7536723
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia.
Mitsuhashi K; Kako S; Shigematsu A; Atsuta Y; Doki N; Fukuda T; Kanamori H; Onizuka M; Takahashi S; Ozawa Y; Kurokawa M; Inoue Y; Nagamura-Inoue T; Morishima Y; Mizuta S; Tanaka J;
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2194-2200. PubMed ID: 27638362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
